Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

NOVO NORDISK A/S (NOVO B)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
11/13/2018 11/14/2018 11/15/2018 11/16/2018 11/19/2018 Date
292.9(c) 294.65(c) 284.5(c) 288.7(c) 297.6 Last
2 665 296 2 607 286 2 252 869 1 896 739 1 500 959 Volume
-1.53% +0.60% -3.44% +1.48% +3.08% Change
More quotes
Financials (DKK)
Sales 2018 111 B
EBIT 2018 47 719 M
Net income 2018 39 083 M
Finance 2018 15 509 M
Yield 2018 2,78%
Sales 2019 117 B
EBIT 2019 50 124 M
Net income 2019 39 800 M
Finance 2019 15 928 M
Yield 2019 2,92%
P/E ratio 2018 17,89
P/E ratio 2019 17,28
EV / Sales2018 4,83x
EV / Sales2019 4,60x
Capitalization 552 B
More Financials
Company
Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products.It operates through the following business segments: Diabetes & Obesity Care, and Biopharmaceuticals.The Diabetes & Obesity Care segment covers products for... 
Sector
Pharmaceuticals
Calendar
12/05Presentation
More about the company
Surperformance© ratings of Novo Nordisk A/S
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVO NORDISK A/S
11/15NOVO NORDISK A/S : Disclosure of transaction data
PU
11/15NOVO NORDISK A/S : - Share repurchase programme
AQ
11/15NOVO NORDISK A/S : World Diabetes Day marked in capital
AQ
11/14NOVO NORDISK A/S : Education Foundation Launches `1000-Day Challenge` to Impact ..
AQ
11/08FASANMADE : 40,000 Nigerians Died of Diabetes in 2017
AQ
11/06NOVO NORDISK A/S : Trading in Novo Nordisk shares by board members, executives a..
AQ
11/05NOVO NORDISK A/S : - Share repurchase programme
AQ
11/05NOVO NORDISK A/S : purchases B shares worth DKK 1,262 million from Novo Holdings..
AQ
11/03NOVO NORDISK A/S : to lay off 1,300 employees
AQ
11/02NOVO NORDISK A/S : Trading in Novo Nordisk shares by board members, executives a..
AQ
More news
Sector news : Pharmaceuticals - NEC
08:48aInvestors Look Past Rout in Tech Stocks -- WSJ
DJ
11/18Why the Corporate Earnings Boom Has Failed to Lift Investors' Spirits
DJ
11/17PFIZER : to Raise Prices On 41 Drugs In January
DJ
11/17PFIZER : to Raise Prices on 41 Drugs -- Update
DJ
11/16NOVARTIS : FDA Approves Novartis Drug Promacta for New Indications
DJ
More sector news : Pharmaceuticals - NEC
MarketScreener Strategies on NOVO NORDISK A/S 
NOVO NORDISK A/S - 10/31
Attractive timing with a long term view to go long again
BUY
NOVO NORDISK A/S - 08/24
The technical configuration is positive
BUY
More Strategies
Latest Tweets
11/14Today is . The day was first introduced in 1991 to spread awareness about dia..
33
11/14It's , and South Africans have been urged to undergo regular screenings. The ..
16
11/08Novo Nordisk A/S’s $NVO Sell Rating Reiterated at HSBC  
11/07$NOVO B Nordisk A/S B 1 director sold: A director at Novo Nordisk AS sold 4,.. 
11/06$novob Nordisk ... NOVO NORDISK: Trulicity will fight hard against Ozempic |.. 
More tweets
Qtime:64
News from SeekingAlpha
11/16European advisory group backs Novo's N8-GP for hemophilia A 
11/15Uncover Managements' Capital Allocation Skills 
11/13Express Scripts launches new formulary aimed at reducing drug costs 
11/08PROJECT $1M TURNS 3 : My Learnings In Running A Growth Portfolio 
11/05NICHOLAS WARD'S DIVIDEND GROWTH PORT : October Update 
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 317  DKK
Spread / Average Target 10,0%
EPS Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S-13.69%84 473
JOHNSON & JOHNSON4.49%391 542
PFIZER20.13%252 358
NOVARTIS6.38%222 056
ROCHE HOLDING LTD.1.54%214 508
MERCK AND COMPANY35.17%197 785